DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetate; CPP; Dabu ying pills; Dihuang; Enantone; GnRH; GnRH agonist; Gold; Gonadorelin; Gonadorelin acetate and Triptorelin acetate; Histrelin; Histrelin Subcutaneous Implant; LA; LEUPRORELIN ACETATE; Leuplin; Leuplin DPS 11.25mg; Leuprolide; Leuprolide (GnRH agonists); Leuprolide Acetate (LA); Leuprolide Acetate 3 Month Depot; Leuprolide Acetate 45 mg; Leuprolide acetate 11.25 mg; Leuprolide acetate 30 mg; Leuprolide acetate depot; Leuprorelin; Leuprorelin Acetate 3.75mg Injection; Luphere depot 3.75mg(Leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Megestrol Acetate Tablet; Megestrol acetate; RhGH; TRIPTORELIN; Trade name depends on the source of the product; Trade name depends on the source of the product’; Triptorelin; Triptorelin (GnRH agonists); Triptorelin acetate and Gonadorelin acetate; Triptorelin embonate, Triptorelin pamoate; Triptorlin or Leuprorelin; Zhibo dihuang pills; Ziyinxiehuo Granules Herbs

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-004494-16-Outside-EU/EEA (EUCTR)		03/12/2014	A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty	A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty	Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product ’ INN or Proposed INN: LEUPRORELIN ACETATE	Abbvie previously known as Abbott	NULL	NA			Female: yes Male: yes	72		United States;Puerto Rico

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-004494-16-Outside-EU/EEA
(EUCTR)

03/12/2014

A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty

A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty

Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product ’
INN or Proposed INN: LEUPRORELIN ACETATE

Abbvie previously known as Abbott

NULL

Female: yes
Male: yes

United States;Puerto Rico